ATE277641T1 - Verfahren zur selektion eines salzes zur herstellung eines inklusionskomplexes - Google Patents

Verfahren zur selektion eines salzes zur herstellung eines inklusionskomplexes

Info

Publication number
ATE277641T1
ATE277641T1 AT97302821T AT97302821T ATE277641T1 AT E277641 T1 ATE277641 T1 AT E277641T1 AT 97302821 T AT97302821 T AT 97302821T AT 97302821 T AT97302821 T AT 97302821T AT E277641 T1 ATE277641 T1 AT E277641T1
Authority
AT
Austria
Prior art keywords
salt
solubility
selecting
producing
inclusion complex
Prior art date
Application number
AT97302821T
Other languages
English (en)
Inventor
Yesook Kim
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Application granted granted Critical
Publication of ATE277641T1 publication Critical patent/ATE277641T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Nanotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Seasonings (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
AT97302821T 1996-05-07 1997-04-24 Verfahren zur selektion eines salzes zur herstellung eines inklusionskomplexes ATE277641T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US1686696P 1996-05-07 1996-05-07

Publications (1)

Publication Number Publication Date
ATE277641T1 true ATE277641T1 (de) 2004-10-15

Family

ID=21779426

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97302821T ATE277641T1 (de) 1996-05-07 1997-04-24 Verfahren zur selektion eines salzes zur herstellung eines inklusionskomplexes

Country Status (9)

Country Link
US (1) US20010007862A1 (de)
EP (1) EP0811386B1 (de)
JP (2) JP3007312B2 (de)
AT (1) ATE277641T1 (de)
CA (1) CA2204451C (de)
DE (1) DE69730902T2 (de)
DK (1) DK0811386T3 (de)
ES (1) ES2224205T3 (de)
PT (1) PT811386E (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA57734C2 (uk) 1996-05-07 2003-07-15 Пфайзер Інк. Комплекси включення арилгетероциклічних солей
IL127497A (en) * 1997-12-18 2002-07-25 Pfizer Prod Inc Medicinal products containing piperazinyl-heterocyclic compounds for the treatment of psychiatric disorders
EP1346224B1 (de) * 2000-10-19 2017-03-01 Mycartis N.V. Verfahren zur manipulation von mikroträgern zu identifizierungszwecken
US6884885B2 (en) 2000-12-21 2005-04-26 Cerestar Holding B.V. Production of cyclodextrin complexes
DE10215942A1 (de) * 2002-04-11 2003-10-23 Bayer Ag Wässrige Formulierungen von (2-Hydroxymethyl-indanyl-4-oxy)-phenyl-4,4,4-trifluorbutan-1-sulfonat
EP1562546A1 (de) * 2002-10-25 2005-08-17 Pfizer Products Inc. Depotformulierungen arylheterozyklischer wirkstoffen in form von suspensionen
US20050266398A1 (en) * 2004-06-01 2005-12-01 Peter Lea Method and device for rapid detection and quantitation of macro and micro matrices
US20080300173A1 (en) * 2004-07-13 2008-12-04 Defrees Shawn Branched Peg Remodeling and Glycosylation of Glucagon-Like Peptides-1 [Glp-1]
CA2475240A1 (en) * 2004-07-20 2006-01-20 Biophys, Inc. Method and device to measure dynamic internal calibration true dose response curves
CA2475191A1 (en) * 2004-07-20 2006-01-20 Biophys, Inc. System and method for rapid reading of macro and micro matrices
CA2475456A1 (en) 2004-07-20 2006-01-20 Biophys, Inc. Method and device to optimize analyte and antibody substrate binding by least energy adsorption
CA2593497A1 (en) * 2005-02-11 2006-08-17 Judith Aronhime Amorphous ziprasidone mesylate
EP1742943A1 (de) * 2005-02-11 2007-01-17 Teva Pharmaceutical Industries Ltd Verfahren zur bereidung von ziprasidon mesylat
EP1858891A2 (de) * 2005-03-14 2007-11-28 Teva Pharmaceutical Industries Ltd. Kristalline formen von ziprasidonmesylat
WO2006099452A1 (en) * 2005-03-14 2006-09-21 Teva Pharmaceutical Industries Ltd. Anhydrous ziprasidone mesylate and a process for its preparation
CA2569971A1 (en) * 2006-12-04 2008-06-04 Umedik Inc. Method for double-dip substrate spin optimization of coated micro array supports
WO2011080749A1 (en) * 2009-12-29 2011-07-07 Hetero Research Foundation Process for purification of ziprasidone

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1269578B (it) * 1994-04-22 1997-04-08 Chiesi Farma Spa Complessi di inclusione multicomponente ad elevata solubilita' costituiti da un farmaco di tipo acido, una ciclodestrina e una base.
UA57734C2 (uk) * 1996-05-07 2003-07-15 Пфайзер Інк. Комплекси включення арилгетероциклічних солей

Also Published As

Publication number Publication date
JP3007312B2 (ja) 2000-02-07
ES2224205T3 (es) 2005-03-01
US20010007862A1 (en) 2001-07-12
EP0811386B1 (de) 2004-09-29
DE69730902D1 (de) 2004-11-04
EP0811386A2 (de) 1997-12-10
JP2000086539A (ja) 2000-03-28
MX9703304A (es) 1998-05-31
DE69730902T2 (de) 2006-02-23
EP0811386A3 (de) 1999-02-10
PT811386E (pt) 2004-12-31
CA2204451C (en) 2004-06-29
CA2204451A1 (en) 1997-11-07
DK0811386T3 (da) 2005-01-03
JPH1059871A (ja) 1998-03-03

Similar Documents

Publication Publication Date Title
ATE277641T1 (de) Verfahren zur selektion eines salzes zur herstellung eines inklusionskomplexes
DE69227056D1 (de) Verfahren zur Fehleranalyse unter Verwendung eines Elektronenstrahles
DE58903372D1 (de) Verfahren zur herstellung eines 1-olefinpolymers.
DE69707145D1 (de) Verfahren zur herstellung eines aldehyds
DE69435092D1 (de) Verfahren zur Herstellung einer optischen Kompensationsfolie
DE69426201D1 (de) Verfahren zur herstellung eines antitranspirantstifter
DE60042601D1 (de) Verfahren zur regelung des nullpunktpotentials eines wandlers mit nullpunktbegrenzung
DE69003090D1 (de) Kalibrierungsverfahren eines dreidimensionalen formerfassungssystems und system zur durchführung des genannten verfahrens.
DE3584179D1 (de) Verfahren zur herstellung eines insulinaehnlichen wachstumsfaktors i.
DE69101432D1 (de) Verfahren zur meeresseismischendatenerfassung.
DE3686842D1 (de) Verfahren zur herstellung eines optischen transmissionsmediums.
DE69233414D1 (de) Verfahren zur bestimmung eines alternativen leitweges
DE50214846D1 (de) Verfahren zur Erkennung und Verfolgung von Objekten
DE69108627D1 (de) Verfahren zum Herstellen eines amorphen, magnetischen Films.
DE69108938D1 (de) Verfahren zur Herstellung eines Feldeffekttransistors mit einer LDD-Struktur.
DE69422557D1 (de) Verfahren zur herstellung chromhaltiger rostfreier stahlbänder mit ausgezeichneter zähigkeit
DE69215983D1 (de) Verfahren zur Messung der Konzentration eines Immuno-Reaktanden unter Verwendung von Elektrochemilumineszenz
DE69819857D1 (de) Verfahren zur herstellung eines optischen leiters
DE69318380D1 (de) Verfahren zur Herstellung eines Orientierungsfilmes
DE58904509D1 (de) Verfahren zur herstellung eines elastomerhaltigen vinylchloridpfropfcopolymerisats.
DE69101150D1 (de) Verfahren zum Lokalisieren eines Fehlers.
DE69213778D1 (de) Verfahren zur Herstellung eines opto-elektronischen Bauteils
DE69029290D1 (de) Verfahren zur herstellung eines 2,2-difluorpropans
ATE192628T1 (de) Verfahren zur herstellung eines einbügelbaren einlagestoffs
DE68907209D1 (de) Verfahren zur herstellung eines supraleitfaehigen duennfilmes.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0811386

Country of ref document: EP

REN Ceased due to non-payment of the annual fee